Fingolimod therapy in early multiple sclerosis: An efficacy analysis of the transforms and freedoms studies by time since first symptom

CNS Neuroscience and Therapeutics

Volumn 20, Issue 5, 2014, Pages 446-451

  Agius, Mark ^a,b   Meng, Xiangyi ^c   Chin, Peter ^c   Grinspan, Augusto ^c   Hashmonay, Ronny ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Veteran's Healthcare System   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Early medical intervention; Fingolimod; Interferon ; Pharmacotherapy; Relapse

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GADOLINIUM; PLACEBO; BETA INTERFERON; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC USE; KAPLAN MEIER METHOD; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TIME; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; FEMALE; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SECONDARY PREVENTION; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898688274     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12235     Document Type: Article

References (23)

1. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782.
2. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-1929.
3. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; U. B. C. Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-1623.
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. predictive value of the early clinical course. Brain 1989;112:1419-1428.
5. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532.
6. Prosperini L, Gianni C, Barletta V, et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 2012;323:104-112.
7. Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008;14:479-484.
8. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848-853.
9. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol 2010;67:1329-1335.
10. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268-275.
11. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010;75:302-309.
12. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77:1684-1690.
13. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009;66:513-520.
14. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
15. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.
16. Davies S, Nicholson T, Laura M, Giovannoni G, Altmann DM. Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. J Neuropathol Exp Neurol 2005;64:371-377.
17. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000;123(Pt 3):508-518.
18. Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 2008;79:1368-1374.
19. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
20. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
21. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-1078.
22. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
23. Miller SD, Eagar TN. Functional role of epitope spreading in the chronic pathogenesis of autoimmune and virus-induced demyelinating diseases. Adv Exp Med Biol 2001;490:99-107.